Telix Pharmaceuticals: Receives approval from U.S FDA for ZIRCON study
- Telix Pharmaceuticals (TLX) has received approval from the U.S. Food and Drug Administration for the ZIRCON study
- The ZIRCON study is an international Phase III study to evaluate the utility of Telix’s product which treats clear cell renal cancer
- Receipt of an Investigational New Drug notice of allowance will enable patient recruitment to begin in the U.S. in 30 days
- In 2018 more than 400,000 people worldwide were diagnosed with kidney cancer and more than 175,000 died from it
- Then the trial expected to complete enrolment in the mid-year
- Telix has also ended the day up 3.45 per cent with shares trading for $1.50 each